DRMA — Dermata Therapeutics, Inc. Dilution Risk Tracker

Dermata Therapeutics, Inc. (DRMA) carries a DilutionScore of 87/100, placing it in the Critical dilution risk tier — the highest category tracked by DilutionWatch. Companies at this level typically have active capital-raising programs, compressed cash runway, or a combination of dilution vectors that together represent meaningful downside risk to share count. As of July 14, 2026, this score reflects real-time data pulled directly from SEC EDGAR filings.

DilutionWatch tracks 5.4M outstanding warrants for DRMA. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: DRMA has approximately 10 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for DRMA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for DRMA alongside comparable critical-risk stocks. Not financial advice — this analysis is for informational purposes only.